Protara Therapeutics (NASDAQ: TARA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.960 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Protara Therapeutics (NASDAQ: TARA) through any online brokerage.
Other companies in Protara Therapeutics’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Virios Therapeutics (NASDAQ:VIRI), Acurx Pharmaceuticals (NASDAQ:ACXP), Synaptogenix (NASDAQ:SNPX) and Celyad Oncology (NASDAQ:CYAD).
The latest price target for Protara Therapeutics (NASDAQ: TARA) was reported by HC Wainwright & Co. on Monday, May 9, 2022. The analyst firm set a price target for 30.00 expecting TARA to rise to within 12 months (a possible 782.35% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Protara Therapeutics (NASDAQ: TARA) is $3.4 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Protara Therapeutics.
Protara Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Protara Therapeutics.
Protara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.